Skip to main content

Vipergen ApS
Gammel Kongevej 23A
1st floor
1610 Copenhagen
Denmark 

VAT: DK28851758

Partnering with Vipergen
From straightforward Fee-For-Service to comprehensive joint ventures, we provide flexible partnership structures to align with your project’s distinct needs.
Explore our services
Partners
Company
Resources
Latest news

Commercial release of the first technology for DEL screening inside a living cell

Written by admin on . Posted in News. No Comments on Commercial release of the first technology for DEL screening inside a living cell

Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process. Main attributes include, 1) lowering the attrition rate in drug discovery since the screening is performed under physiological relevant conditions, and 2) expanding the DEL amenable target space since no requirement for highly purified active target protein. Vipergen is offering small molecule drug discovery services employing the technology under different business models, including simple Fee-For-Service

“We are very excited about this transformative technology which is a major step forward for the fast-growing field of small molecule drug discovery based on DELs.” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen is now able to screen a wider range of challenging target proteins and a lower attrition rate is expected because we screen under physiological relevant conditions. Furthermore, this technology uniquely allows us to engage in large scale screenings campaigns of hundreds, even thousands of protein targets per year, because the input is the target gene, and thereby eliminates the need for purified active protein, which require work, are more delicate, and require tailor-made screening conditions.”

About Vipergen ApS

Vipergen is a world leading provider of small molecule drug discovery services based on DNAencoded library (DEL) technologies

Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies

Vipergen is offering different business models, including simple Fee-For-Service. In 2015-20 >40 deals signed, including with top-5 pharma in both USA, EU and Japan

For further details about Vipergen and the YoctoReactor® / Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact:

Vipergen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
[email protected]

Vipergen enters into multi-target drug discovery agreement with Merck

Written by admin on . Posted in News. No Comments on Vipergen enters into multi-target drug discovery agreement with Merck

Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Merck. Under the terms of the agreement, Vipergen’s small molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits for selected targets from Merck. Merckobtains exclusive options to selected hits/leads and hit/lead series. The therapeutic areas of the targets were not disclosed, nor were the financial details of theagreement.

“We are very proud to be selected by Merck, a global industry leader in drug discovery and development.” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen has designed and implemented its discovery engine to deliver high quality hits and leads for very challenging but important protein targets as Merckis tackling to address unmet medical needs. We look forward to working with Merck.”

About Vipergen ApS

Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.Vipergen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies. Vipergen ́s two 2ndgenerationtechnology platforms -The YoctoReactor®for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment®for screening of such libraries -are designed to deliver high fidelity drug discovery. For further details about Vipergen and the YoctoReactor®/ Binder Trap Enrichment®drug discovery technology platforms please visit www.vipergen.com or contact:

 

Vipergen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
[email protected]

Vipergen enters into multi-target drug discovery agreement with Daiichi Sankyo

Written by admin on . Posted in News. No Comments on Vipergen enters into multi-target drug discovery agreement with Daiichi Sankyo

Vipergen ApS announced today the signing of a multi-target drug discovery agreement with Daiichi Sankyo Co., Ltd. (hereinafter “Daiichi Sankyo”). Under the terms of the agreement, Vipergen’ssmall molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits/leads for selected targets from Daiichi Sankyo. Daiichi Sankyoobtains exclusive options to selected hits/leads and hit/lead series. The therapeutic areas of the targets were not disclosed. No information about the financial arrangement was provided.

“We are very proud to be selected by Daiichi Sankyo, a global industry leader in drug discovery and development.” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen has designed and implemented its discovery engine to deliver high quality hits and leads for very challenging but important protein targets as Daiichi Sankyo is tackling to address unmet medical needs. We look forward to working with Daiichi Sankyo.”


About Daiichi Sankyo Company

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to astrong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,”Daiichi Sankyoresearch and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizonareas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.


About Vipergen ApS

Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

Vipergen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies.

Vipergen ́s two 2ndgeneration technology platforms -The YoctoReactor®for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment®for screening of such libraries -are designed to deliver high fidelity drug discovery.

For further details about Vipergen and the YoctoReactor®/ Binder Trap Enrichment®drug discovery technology platformsplease visit www.vipergen.com or contact:

Vipergen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
[email protected]

Vipergen enters into multi-target drug discovery agreement with Gilead

Written by admin on . Posted in News. No Comments on Vipergen enters into multi-target drug discovery agreement with Gilead

Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary second
generation DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Gilead Sciences, Inc.

Under the terms of the agreement, Vipergen is applying its small molecule discovery engine, which leverages a high fidelity proprietary DNA-encoded library platform, to identify novel hits/leads for protein targets specified by Gilead. Gilead obtains exclusive options to selected hits and hit series discovered in the course of the collaboration. Other terms of the agreement were not disclosed.

“We are thrilled to work with Gilead, one of the world’s leading biopharmaceutical companies, on targets which are difficult from a drug discovery standpoint,” said Nils Hansen, Ph.D., Chief Executive Officer of Vipergen. “Vipergen has designed and implemented its discovery engine to meet the challenges of such highly difficult targets.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

About Vipergen ApS

Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

Vipergen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

Vipergen´s two second generation technology platforms – The YoctoReactor® for synthesizing DNAencoded chemical libraries and Binder Trap Enrichment® for screening of such libraries – are designed to deliver high fidelity drug discovery.

For further details about Vipergen and the YoctoReactor® / Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact:

Vipergen ApS
Dr. Nils Hansen, Chief Executive Officer
Phone: +45 2523 6680
[email protected]

Vipergen enters into multi-target collaboration with Europes largest biopharmaceutical company

Written by admin on . Posted in News. No Comments on Vipergen enters into multi-target collaboration with Europes largest biopharmaceutical company

Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2 nd generation DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Actelion Pharmaceuticals Ltd (a subsidiary of Actelion Ltd, SIX: ATLN), a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Under the terms of the agreement, Vipergen is applying its small molecule discovery engine, which leverages a high fidelity proprietary DNA-encoded library platform to identify novel hits/leads for selected targets from Actelion. Actelion obtains exclusive options to selected hits and hit series. The therapeutic area of the targets was not disclosed. No information about the financial arrangement was provided.

About Actelion Ltd

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.

About Vipergen ApS

Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

Vipergen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

Vipergen´s two 2 nd generation technology platforms – The YoctoReactor® for synthesizing DNAencoded chemical libraries and Binder Trap Enrichment®
for screening of such libraries – are designed to deliver high fidelity drug discovery.

Vipergen enters into multi-target drug discovery agreement with Amgen

Written by admin on . Posted in News. No Comments on Vipergen enters into multi-target drug discovery agreement with Amgen

Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary 2nd generation DNA-encoded library platform, today announced the signing of a drug discovery agreement with Amgen Inc., a global leader in the biotech industry.

Under the terms of the agreement, Vipergen’s small molecule discovery engine will be applied across therapeutic areas to identify novel hits/leads for selected targets from Amgen. Amgen obtains exclusive options to hits and leads discovered in the course of the collaboration. Other terms of the agreement were not disclosed.

“We are very excited to work with Amgen, recognized as one of the world’s most successful biotech companies,” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen’s small molecule discovery engine is designed to deliver high quality hits and leads for very challenging and important protein targets, such as those Amgen is tackling. We look forward to working with the excellent scientific team at Amgen to help transform their important discoveries into novel therapies for patients with serious illnesses.“

About Vipergen ApS

Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

Vipergen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies.

Vipergen´s two 2nd generation technology platforms – The YoctoReactor® for synthesizing DNAencoded chemical libraries and Binder Trap Enrichment®
for screening of such libraries – are designed to deliver high fidelity drug discovery.

For further details about Vipergen and the YoctoReactor®/ Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact:

Vipergen ApS
Dr. Nils Hansen, Chief Executive Officer
Phone: +45 2523 6680
[email protected]

Menu

About us

Mail
Menu

About us

Mail